Metabolomics and clinical evaluation of Jiedu Tongluo Tiaogan Decoction in the treatment of type 2 diabetes mellitus combined with nonalcoholic fatty liver disease

Shenzhen Hospital of Guangzhou University of traditional Chinese medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

试验速览

暂无简介。

•(1) All the patients meet the diagnostic criteria for type 2 diabetes and non-alcoholic fatty liver disease, and HbA1c is less than 10%.
•(2) Aged between 20-75 years;
•(3) Liver function is basically normal: AST or ALT < 2.5 times the upper limit of normal, and total bilirubin was normal;
•(4) The experimental group did not receive oral treatment of diabetes or non-alcoholic fatty liver at least 2 weeks before admission. The control group did not use hypoglycemic drugs or drugs for the treatment of nonalcoholic fatty liver at least 3 days before joining the group; The effects of drugs on metabolism were excluded.
•(5) All experimental personnel voluntarily participated in the clinical study, signed informed consent and have good compliance.

•(1) Those who do not meet the diagnostic criteria and inclusion criteria;
•(2) Those who cannot carry out the experiment according to the research procedures, including patients with chronic diseases such as cardiovascular and cerebrovascular diseases and mental diseases;
•(3) Patients treated with insulin;
•(4) Patients whose condition changes make it difficult to evaluate the effectiveness and safety of the intervention, such as those with severe liver and kidney dysfunction;
•(5) Allergic constitution or uncomfortable symptoms after taking drugs or a history of drug allergy;
•(6) Pregnant and lactating women;
•(7) Patients who participated in other clinical studies in recent 3 months.
•If any one of the above items is met, it shall not be selected.

发起方

Shenzhen Hospital of Guangzhou University of traditional Chinese medicine